Clinical Trials

This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.

The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points.

The purpose of this study is to determine the safety and effectiveness of IPI-926 for the treatment of patients who have myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 

The purpose of this study is to assess the safety and effectiveness of Aplidin® (plitidepsin) for the treatment of Patients who have primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis.

The purpose of this study is to find out the safe dose range of the study drug in patients who have myeloproliferative disorders.

The purpose of this study is to better understand the role of survey assessment in symptom evaluation of patient with chronic hematologic malignancies.

The purpose of this study is to develop a data-driven approach that enables healthcare providers to “prescribe” exercise in the appropriate dose in a manner analogous to prescribing a drug.